Company profile for Vaxxinity

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with operations in the United States, Latin America, Europe and Asia, the company’s proprietary technology platform has enabled the innovation of synthetic peptide vaccines designed to prevent or treat infectious diseases, including COVID-19, and chronic diseases, including Alzheimer'...
Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with operations in the United States, Latin America, Europe and Asia, the company’s proprietary technology platform has enabled the innovation of synthetic peptide vaccines designed to prevent or treat infectious diseases, including COVID-19, and chronic diseases, including Alzheimer's, Parkinson’s, migraine, and hypercholesterolemia.. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1717 Main St, Suite 3388 Dallas, TX 75201
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/06/20/2901487/0/en/Vaxxinity-UB-312-Parkinson-s-Trial-Results-Published-in-Nature-Medicine.html

GLOBENEWSWIRE
20 Jun 2024
Vaxxinity retreats from 'abusive relationship' of public market
Vaxxinity retreats from 'abusive relationship' of public market

15 May 2024

// Annalee Armstrong FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/vaxxinity-retreats-abusive-relationship-after-3-years-public-markets

Annalee Armstrong FIERCE BIOTECH
15 May 2024
Vaxxinity Issues Shareholder Letter
Vaxxinity Issues Shareholder Letter

19 Apr 2024

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2024/04/19/2866409/0/en/Vaxxinity-Issues-Shareholder-Letter.html

GLOBENEWSWIRE
19 Apr 2024

https://www.globenewswire.com/news-release/2024/04/19/2866373/0/en/Vaxxinity-Announces-Intention-to-Voluntarily-Delist-and-Deregister-its-Class-A-Common-Stock.html

GLOBENEWSWIRE
19 Apr 2024

https://www.globenewswire.com/news-release/2024/03/28/2854092/0/en/Vaxxinity-to-Present-Clinical-Data-at-the-Annual-Academy-of-Neurology-2024-Annual-Meeting.html

GLOBENEWSWIRE
28 Mar 2024

https://www.globenewswire.com/news-release/2024/03/27/2853637/0/en/Vaxxinity-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Updates.html

GLOBENEWSWIRE
27 Mar 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty